Mendus reports complete enrollment of the first stage of the VITAL-CML trial
Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announced successful recruitment of the first stage of the VITAL-CML trial, comprising the first 8 patients. This marks an important milestone in the development of the compan…